 |
 |
 |
 |
 |
 |
 |
 |
| Senesco is a cancer therapeutics company employing its strong proprietary platform in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate cell death and survival. The Company's lead therapeutic candidate SNS01-T incorporates recent developments in siRNA, DNA regulation and nanotechnology. Senesco is building its portfolio with other potential eiF5A applications in cancer, inflammation and ischemia. |
| Clinical Trials | ||
| Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. For contact information, please visit the study page on clinicaltrials.gov. |
